Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3000580rdf:typepubmed:Citationlld:pubmed
pubmed-article:3000580lifeskim:mentionsumls-concept:C0007994lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C1510411lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C1257741lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C0006674lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C0029282lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C0033640lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:3000580lifeskim:mentionsumls-concept:C1627358lld:lifeskim
pubmed-article:3000580pubmed:issue2lld:pubmed
pubmed-article:3000580pubmed:dateCreated1986-2-20lld:pubmed
pubmed-article:3000580pubmed:abstractTextWe reported previously that 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3], a hormonally active form of vitamin D3, markedly enhanced methylcholanthrene-induced transformation of BALB 3T3 A31-1-1 cells. When the cells were treated with methylcholanthrene (1 microgram/ml) for 72 h and then with 1 alpha,25(OH)2D3 (5 ng/ml) for 2 wk, the transformation frequency was 1.95 +/- 0.73 (SD) foci/dish in 8 independent experiments, which was about 20 times that in cultures treated with methylcholanthrene only. Even at a physiological concentration in plasma, i.e., 0.05 ng/ml, 1 alpha,25(OH)2D3 enhanced the transformation frequency significantly (P less than 0.001). 1 alpha,25(OH)2D3 was not cytotoxic but slightly inhibited growth of the cells. Cells treated with 1 alpha,25(OH)2D3 were thin and became arranged in a meshwork with wide intercellular spaces. These morphological changes were reversible. 1 alpha,25(OH)2D3 induced DNA synthesis in quiescent BALB 3T3 cells dose and time dependently, but this effect was less than that of 12-O-tetradecanoylphorbol-13-acetate. Unlike 12-O-tetradecanoylphorbol-13-acetate, 1 alpha,25(OH)2D3 did not interfere with the binding of epidermal growth factor or phorbol dibutyrate. 1 alpha,25(OH)2D3 did not induce ornithine decarboxylase. Moreover, it did not activate protein kinase C in quiescent BALB 3T3 cells or this enzyme isolated from mouse brain. BALB 3T3 cells and their transformants contain a specific cytosol receptor for 1 alpha,25(OH)2D3, but the binding sites of the transformants were fewer and had lower affinity than those of untransformed BALB 3T3 cells. These effects of 1 alpha,25(OH)2D3 were specific, because other derivatives of vitamin D3 induced the same effects only at 200 times or more higher concentrations.lld:pubmed
pubmed-article:3000580pubmed:languageenglld:pubmed
pubmed-article:3000580pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:citationSubsetIMlld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3000580pubmed:statusMEDLINElld:pubmed
pubmed-article:3000580pubmed:monthFeblld:pubmed
pubmed-article:3000580pubmed:issn0008-5472lld:pubmed
pubmed-article:3000580pubmed:authorpubmed-author:AbeEElld:pubmed
pubmed-article:3000580pubmed:authorpubmed-author:SasakiKKlld:pubmed
pubmed-article:3000580pubmed:authorpubmed-author:KurokiTTlld:pubmed
pubmed-article:3000580pubmed:authorpubmed-author:SudaTTlld:pubmed
pubmed-article:3000580pubmed:authorpubmed-author:KamataNNlld:pubmed
pubmed-article:3000580pubmed:authorpubmed-author:HashibaHHlld:pubmed
pubmed-article:3000580pubmed:authorpubmed-author:ChidaKKlld:pubmed
pubmed-article:3000580pubmed:issnTypePrintlld:pubmed
pubmed-article:3000580pubmed:volume46lld:pubmed
pubmed-article:3000580pubmed:ownerNLMlld:pubmed
pubmed-article:3000580pubmed:authorsCompleteYlld:pubmed
pubmed-article:3000580pubmed:pagination604-10lld:pubmed
pubmed-article:3000580pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:meshHeadingpubmed-meshheading:3000580-...lld:pubmed
pubmed-article:3000580pubmed:year1986lld:pubmed
pubmed-article:3000580pubmed:articleTitleEnhancement by 1 alpha,25-dihydroxyvitamin D3 of chemically induced transformation of BALB 3T3 cells without induction of ornithine decarboxylase or activation of protein kinase C1.lld:pubmed
pubmed-article:3000580pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3000580pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3000580lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3000580lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3000580lld:pubmed